News & Updates
Filter by Specialty:
Casirivimab-imdevimab combo may reduce hospitalization in mild-to-moderate COVID-19
Treatment with a combination of the recombinant human IgG1 monoclonal antibodies casirivimab and imdevimab reduced hospitalization rates in high-risk patients with mild-to-moderate COVID-19, according to results of a retrospective study.
Casirivimab-imdevimab combo may reduce hospitalization in mild-to-moderate COVID-19
29 Sep 2021
High-flowrate air samplers allow thorough monitoring for airborne SARS-CoV-2
High-flowrate air samplers are able to detect airborne SARS-CoV-2 in hospitals, outperforming even surface sampling, according to a recent Singapore study. Factors such as the site of deployment and distance of the air samplers from patients affect the viral load detected.
High-flowrate air samplers allow thorough monitoring for airborne SARS-CoV-2
28 Sep 2021
Lung function not affected in children, adolescents post-COVID
COVID-19 does not appear to result in long-term impairment of lung function in children and adolescents, according to two studies presented at ERS 2021.
Lung function not affected in children, adolescents post-COVID
27 Sep 2021
SARS-CoV-2 lurks in small airborne particles
Investigations into the role of small aerosol particles in COVID-19 transmission suggest that SARS-CoV-2 may be an airborne hazard. A recent medRxiv preprint study from Singapore adds to this body of evidence.
SARS-CoV-2 lurks in small airborne particles
24 Sep 2021
Tofacitinib may promote HBV reactivation in certain RA patients
Use of tofacitinib for rheumatoid arthritis (RA) may lead to reactivation of hepatitis B virus (HBV), especially among hepatitis B surface antigen-positive (HBsAg+) and HBsAg-negative/hepatitis B core antibody-positive (HBsAg–/HBcAb+) patients, according to a study from Taiwan.
